Medicenna Therapeutics logo

MDNA - Medicenna Therapeutics Share Price

C$5.78 0.3  5.7%

Last Trade - 10/08/20

Small Cap
Market Cap £152.8m
Enterprise Value £129.6m
Revenue £n/a
Position in Universe 462nd / 2675
Unlock MDNA Revenue
Relative Strength (%)
1m -7.95%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 0.10
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 30 June 2020, Medicenna Therapeutics Corp revenues was not reported. Net loss increased 82% to C$2.4M. Higher net loss reflects CPRIT grant claimed in eligible expenses decrease from C$869K (income) to C$0K, General and administration-balancing val increase from C$93K to C$402K (expense), Research and development - Balancing val increase of 10% to C$1.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for MDNA
Graphical History


MDNA Revenue Unlock MDNA Revenue

Net Income

MDNA Net Income Unlock MDNA Revenue

Normalised EPS

MDNA Normalised EPS Unlock MDNA Revenue

PE Ratio Range

MDNA PE Ratio Range Unlock MDNA Revenue

Dividend Yield Range

MDNA Dividend Yield Range Unlock MDNA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MDNA EPS Forecasts Unlock MDNA Revenue
Profile Summary

Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.

Last Annual March 31st, 2020
Last Interim June 30th, 2020
Incorporated February 2, 2015
Public Since July 13, 2015
No. of Shareholders: n/a
No. of Employees: 7
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Toronto Stock Exchange
Shares in Issue 48,797,983
Free Float (0.0%)
Eligible for
MDNA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MDNA
Upcoming Events for MDNA
Frequently Asked Questions for Medicenna Therapeutics
What is the Medicenna Therapeutics share price?

As of 10/08/20, shares in Medicenna Therapeutics are trading at C$5.78, giving the company a market capitalisation of £152.8m. This share price information is delayed by 15 minutes.

How has the Medicenna Therapeutics share price performed this year?

Shares in Medicenna Therapeutics are currently trading at C$5.78 and the price has moved by 0.321k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Medicenna Therapeutics price has moved by 0.315k% over the past year.

What are the analyst and broker recommendations for Medicenna Therapeutics?

Of the analysts with advisory recommendations for Medicenna Therapeutics, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Medicenna Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Medicenna Therapeutics next release its financial results?

Medicenna Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Medicenna Therapeutics dividend yield?

Medicenna Therapeutics does not currently pay a dividend.

Does Medicenna Therapeutics pay a dividend?

Medicenna Therapeutics does not currently pay a dividend.

When does Medicenna Therapeutics next pay dividends?

Medicenna Therapeutics does not currently pay a dividend.

How do I buy Medicenna Therapeutics shares?

To buy shares in Medicenna Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Medicenna Therapeutics?

Shares in Medicenna Therapeutics are currently trading at C$5.78, giving the company a market capitalisation of £152.8m.

Where are Medicenna Therapeutics shares listed? Where are Medicenna Therapeutics shares listed?

Here are the trading details for Medicenna Therapeutics:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: MDNA
What kind of share is Medicenna Therapeutics?

Based on an overall assessment of its quality, value and momentum, Medicenna Therapeutics is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Medicenna Therapeutics share price forecast 2020?

Shares in Medicenna Therapeutics are currently priced at C$5.78. At that level they are trading at 0.108% discount to the analyst consensus target price of 0.00.

Analysts covering Medicenna Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -0.328 for the next financial year.

How can I tell whether the Medicenna Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medicenna Therapeutics. Over the past six months, the relative strength of its shares against the market has been 82.34%. At the current price of C$5.78, shares in Medicenna Therapeutics are trading at 52.32% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Medicenna Therapeutics PE Ratio?

We were not able to find PE ratio data for Medicenna Therapeutics.

Who are the key directors of Medicenna Therapeutics?

We were unable to find the directors for Medicenna Therapeutics.

Who are the major shareholders of Medicenna Therapeutics?

Here are the top five shareholders of Medicenna Therapeutics based on the size of their shareholding:

Aries Biologics, Inc. Corporation
Percentage owned: 11.27% (5.50m shares)
Merchant (Fahar) Individual Investor
Percentage owned: 10.76% (5.25m shares)
Merchant (Rosemina) Individual Investor
Percentage owned: 10.76% (5.25m shares)
iShares S&P/TSX SmallCap Index ETF Mutual Fund
Percentage owned: 0.09% (44.1k shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 0.09% (44.1k shares)
Similar to MDNA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.